Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alx Oncology Holdings Inc (NQ: ALXO )

1.410 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alx Oncology Holdings Inc

< Previous 1 2 3 4 5 Next >
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development 
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces November Investor Conference Participation
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual... 
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal antibody in patients with multiple myeloma 
From ALX Oncology
Via GlobeNewswire
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q2 2024
ALXO stock results show that ALX Oncology Holdings beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
From ALX Oncology
Via GlobeNewswire
Crude Oil Moves Lower; Moderna Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Surges 1%; Meta Posts Upbeat Earnings
Via Benzinga
Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
ALX Oncology announces Phase 2 ASPEN-06 trial results for evorpacept in combination with trastuzumab, Cyramza, and paclitaxel for HER2-positive gastric/GEJ cancer. The trial shows significant... 
Via Benzinga
Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
From ALX Oncology
Via GlobeNewswire
ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024
ALXO stock results show that ALX Oncology Holdings beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
ALX Oncology Appoints Allison Dillon as Chief Business Officer
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
From ALX Oncology
Via GlobeNewswire
United Airlines Reports Upbeat Results, Joins Children's Place, Interactive Brokers And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling over 50 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. 
Via Benzinga
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
From ALX Oncology
Via GlobeNewswire
ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer
ALX Oncology's evorpacept, poised for pivotal HER2+ gastric cancer development. Caution prevails due to sub-$100 million market size; await additional plans backed by phase 1/2 data. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q4 2023
ALXO stock results show that ALX Oncology Holdings beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.